Organ-sparing radiation therapy for head and neck cancer. - sprookjes - yvandenbroek - TriplyDB

Organ-sparing radiation therapy for head and neck cancer.

Organ-sparing radiation therapy for head and neck cancer.

http://www.wikidata.org/entity/Q37905536

about

Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation.Late term tolerance in head neck cancer patients irradiated in the IMRT era.Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment.Noncancer-Related Health Events and Mortality in Head and Neck Cancer Patients After Definitive Radiotherapy: A Prospective Study Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment.Effects of the dose-volume relationship on and risk factors for maxillary osteoradionecrosis after carbon ion radiotherapy.Sparing functional anatomical structures during intensity-modulated radiotherapy: an old problem, a new solution.Predicting depression and quality of life among long-term head and neck cancer survivors.Charged-particle therapy in cancer: clinical uses and future perspectives.Treatment outcome of ion beam therapy in eight patients with head and neck cancers.Radiation dose to the tongue and velopharynx predicts acoustic-articulatory changes after chemo-IMRT treatment for advanced head and neck cancer.Laryngeal cancer in Finland: A 5-year follow-up study of 366 patients.The Effect of Head and Neck Radiotherapy on Blood Pressure and Orthostatic Hypotension in Patients With Head and Neck Tumors.Systematic Review of Normal Tissue Complication Models Relevant to Standard Fractionation Radiation Therapy of the Head and Neck Region Published After the QUANTEC Reports.Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy.Prediction of radiotherapy response with a 5-microRNA signature-based nomogram in head and neck squamous cell carcinoma.XRCC3 polymorphisms are associated with the risk of developing radiation-induced late xerostomia in nasopharyngeal carcinoma patients treated with intensity modulation radiated therapy.Symptom burden and dysphagia associated with osteoradionecrosis in long-term oropharynx cancer survivors: A cohort analysis.

P2860

Q27026696-54106BE3-42AF-4620-B78D-9CDD7B09DD4D Q33911452-1F6661F0-0771-4D63-99A1-94E66B41ADC7 Q34498186-686A2ED3-216D-4600-BC44-F60E267B44DC Q34568221-953E1C42-E74C-4580-A859-58B3E089F7DF Q36993334-CF64FFAF-D5FC-47A0-B9E4-0CD30F7A7254 Q37087450-5BA59568-2F69-4581-B142-EE042B4D8D8F Q37710909-508B1C87-57F6-4971-9BB7-1F9EBCA80FFF Q38132448-282765B7-4B04-404E-98AB-B79DE6502423 Q38268076-ED6ADFB8-4B53-4B13-AACB-5BF3A7711023 Q38746213-96F98790-29A7-47A1-B41A-2ACF40CBCD98 Q40759501-5D1BBED6-46A7-4D74-BF17-3A894DC0CBC5 Q41501145-C6B1E361-0D63-40A7-B9A9-F4DB4BBBFC3F Q45949086-FEA8BB4C-F340-41CE-AB8D-5636B4146A37 Q49556727-A6217169-6F9D-4593-BFF4-C58AD1190DD3 Q49896415-3997C3E6-7D9A-4D0F-A125-0279CE6780DB Q52385231-A70E4E59-696C-41BE-96DA-043A443B4A4D Q52688853-9B9B45A8-7815-4B97-8DC6-BB1CF8A1AB06 Q54226684-2D04868D-3A2F-4FFA-813E-690EF9E557D3 Q55226165-6A1232E8-BF87-4D73-BF3E-7086836AB542

P2860

Organ-sparing radiation therapy for head and neck cancer.

http://www.wikidata.org/entity/Q37905536

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Organ-sparing radiation therapy for head and neck cancer.

@en

Organ-sparing radiation therapy for head and neck cancer.

@nl

type

label

Organ-sparing radiation therapy for head and neck cancer.

@en

Organ-sparing radiation therapy for head and neck cancer.

@nl

prefLabel

Organ-sparing radiation therapy for head and neck cancer.

@en

Organ-sparing radiation therapy for head and neck cancer.

@nl

P1433

Q37905536-2A25820A-2C67-449F-B4A8-2F51A4D31F6C

P1476

Q37905536-F0E66364-825E-4BF2-A793-B1AA4FDD86F5

P2093

Q37905536-3025A63A-B3B6-40E2-A990-5F0947109D58

P2860

Q37905536-007E026B-2137-4D87-880A-3CD8A5B1F796

Q37905536-02C0AF5E-64EC-4BA1-A9F7-D3277E8FF463

Q37905536-04F304C2-693E-4C60-BF12-494C9DC8430A

Q37905536-04FF31F4-3B10-4D3F-B168-A895D21A03D6

Q37905536-08BCF1D2-957D-44B7-B838-344B8474B15F

Q37905536-08F74D5C-355B-437F-B1C9-F41EC1720434

Q37905536-0916812D-D647-40E7-87EF-EB5B6545224C

Q37905536-0ED41F5E-E937-4DD1-9D67-7D3CF562F060

Q37905536-0FEF7E82-4D50-436A-9C27-492FC858146D

Q37905536-11ACD4EC-4AF1-40A0-BF6F-EAF504009E1C

P304

Q37905536-508B429E-417D-4D8D-BC91-EE92219ADF33

P31

Q37905536-A2F2F0EC-6CD7-4C96-B15E-F082E7626794

P356

Q37905536-9E7CF333-075C-4C54-A244-33D1114E012A

P407

Q37905536-7002DF33-6BCA-4743-A420-8BBE12840B64

P433

Q37905536-73428AF9-FD4A-48CA-9FF0-E1323835F3D8

P478

Q37905536-D8C64DEB-5737-4771-A855-738A5466326F

P50

Q37905536-25A49ABE-83FC-431B-983D-6F5494A19834

Q37905536-268F1A9A-1354-41D4-A3FE-5BF3D9AEF60F

Q37905536-EA75356B-5C12-4218-AD12-F50E1372A004

P577

Q37905536-050A89B7-25C9-4E78-8F0A-27C8304DBFFF

P698

Q37905536-F86A3412-0D45-44EF-A7E9-FC9AA876176A

P921

Q37905536-C9EC9B78-CF25-4218-B976-19C8FC989FB4

P356

NRCLINONC.2011.106

P1433

Nature Reviews Clinical Oncology

P1476

Organ-sparing radiation therapy for head and neck cancer.

@en

P2093

XiaoShen Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines.

Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship.

Treatment techniques and site considerations regarding dysphagia-related quality of life in cancer of the oropharynx and nasopharynx.

Results of fiberoptic endoscopic evaluation of swallowing vs. radiation dose in the swallowing muscles after radiotherapy of cancer in the oropharynx.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.

Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22).

Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.

P304

639-648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2011.106

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Avraham Eisbruch

P577

2011-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21788974

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy